Experimental Models of HD and Reflection on Therapeutic Strategies

International Review of Neurobiology

Volumn 98, Issue , 2011, Pages 419-481

  Kim, Jinho ^a   Bordiuk, Olivia L ^b   Ferrante, Robert J ^a,c,d  

^a UPMC Presbyterian   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VA Pittsburgh Healthcare System   (United States)

Author keywords

Autonomous; Autosomal; Excitotoxicity; Huntingtin; Memory impairment; Vesicular

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMANTADINE; BIOLOGICAL MARKER; CHROMOMYCIN; CREATINE; DIMEBON; DNA VACCINE; HISTONE DEACETYLASE INHIBITOR; HUNTINGTIN; ICOSAPENTAENOIC ACID; LENTIVIRUS VECTOR; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; MINOCYCLINE; MITHRAMYCIN; RESERPINE; RILUZOLE; TETRABENAZINE; TRANSFER RNA; UBIDECARENONE; VORINOSTAT;

AGITATION; AKATHISIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BOOK; CELL TRANSPLANTATION; CLINICAL FEATURE; CORPUS STRIATUM; DEPRESSION; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA IMMUNIZATION; DOSE RESPONSE; DROWSINESS; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENERGY METABOLISM; EXCITOTOXICITY; EXPERIMENTAL MODEL; EXPERIMENTAL MONKEY; FEVER; GENE; GENE FREQUENCY; GENETIC MODEL; HUMAN; HUNTINGTIN GENE; HUNTINGTON CHOREA; HYPERKINESIA; INSOMNIA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NAUSEA; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TREATMENT PLANNING; VOMITING;

EID: 80052528377     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381328-2.00016-X     Document Type: Chapter

References (325)

1. Alam Z.I., Halliwell B., Jenner P. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J. Neurochem. 2000, 75:840-846.
2. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology 1992, 42:733-738.
3. Alexi T., Hughes P.E., Knusel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp. Neurol. 1998, 153:74-93.
4. Alston T.A., Mela L., Bright H.J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad. Sci. USA 1977, 74:3767-3771.
5. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
6. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
7. Augood S.J., Faull R.L., Emson P.C. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 1997, 42:215-221.
8. Bachoud-Levi A., Bourdet C., Brugieres P., Nguyen J.P., Grandmougin T., Haddad B., Jeny R., Bartolomeo P., Boisse M.F., Barba G.D., Degos J.D., Ergis A.M., Lefaucheur J.P., Lisovoski F., Pailhous E., Remy P., Palfi S., Defer G.L., Cesaro P., Hantraye P., Peschanski M. Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease. Exp. Neurol. 2000, 161:194-202.
9. Bachurin S., Bukatina E., Lermontova N., Tkachenko S., Afanasiev A., Grigoriev V., Grigorieva I., Ivanov Y., Sablin S., Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. NY Acad. Sci. 2001, 939:425-435.
10. Bachurin S.O, Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. NY Acad. Sci. 2003, 993:334-344. discussion 345-339.
11. Barker R.A., Widner H. Immune problems in central nervous system cell therapy. NeuroRx 2004, 1:472-481.
12. Beal M.F, Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 2004, 5:373-384.
13. Beal M.F., Kowall N.W., Swartz K.J., Ferrante R.J., Martin J.B. Systemic approaches to modifying quinolinic acid striatal lesions in rats. J. Neurosci. 1988, 8:3901-3908.
14. Beal M.F., Swartz K.J., Finn S.F., Mazurek M.F., Kowall N.W. Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J. Neurosci. 1991, 11:147-158.
15. Beal M.F., Ferrante R.J., Swartz K.J., Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 1991, 11:1649-1659.
16. Beal M.F., Swartz K.J., Hyman B.T., Storey E., Finn S.F., Koroshetz W. Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J. Neurochem. 1991, 57:1068-1073.
17. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
18. Beal M.F., Henshaw R., Jenkins B.G., Rosen B.R., Schulz J.B. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol. 1994, 36:882-888.
19. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. Neurol. 1992, 31:119-130.
20. Beal M.F. Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta 1998, 1366:211-223.
21. Beal M.F. Mitochondria, NO and neurodegeneration. Biochem. Soc. Symp. 1999, 66:43-54.
22. Benard G., Bellance N., James D., Parrone P., Fernandez H., Letellier T., Rossignol R. Mitochondrial bioenergetics and structural network organization. J. Cell Sci. 2007, 120:838-848.
23. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
24. Bender A., Auer D.P., Merl T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 2005, 2005:36-41.
25. Bessman S.P., Geiger P.J. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 1981, 211:448-452.
26. Bird E.D, Iversen L.L. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 1974, 97:457-472.
27. Bizat N., Hermel J.M., Humbert S., Jacquard C., Creminon C., Escartin C., Saudou F., Krajewski S., Hantraye P., Brouillet E. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 2003, 278:43245-43253.
28. Biziere K., Coyle J.T. Effects of cortical ablation on the neurotoxicity and receptor binding of kainic acid in striatum. J. Neurosci. Res 1979, 4:383-398.
29. Blum D., Galas M.C., Gall D., Cuvelier L., Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 2002, 10:410-426.
30. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 1998, 71:2642-2644.
31. Bogdanov M.B., Andreassen O.A., Dedeoglu A., Ferrante R.J., Beal M.F. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 2001, 79:1246-1249.
32. Bonelli R.M., Heuberger C., Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 2003, 60:883-884.
33. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. USA 2005, 102:11023-11028.
34. Braak H., Braak E. Allocortical involvement in Huntington's disease. Neuropathol. Appl. Neurobiol. 1992, 18:539-547.
35. Brennan W.A., Bird E.D., Aprille J.R. Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 1985, 44:1948-1950.
36. Brooks S., Higgs G., Jones L., Dunnett S.B. Longitudinal analysis of the behavioural phenotype in Hdh((CAG)150) Huntington's disease knock-in mice. Brain Res. Bull. 2010.
37. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., Roy D.S., Rosen B.R., Beal M.F. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 1993, 60:356-359.
38. Brouillet E., Guyot M.C., Mittoux V., Altairac S., Conde F., Palfi S., Hantraye P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 1998, 70:794-805.
39. Brouillet E, Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95:1521-1540.
40. Browne S.E., Beal M.F. Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases. Biochem. Soc. Trans. 1994, 22:1002-1006.
41. Browne S.E., Beal M.F. Oxidative damage in Huntington's disease pathogenesis. Antioxid. Redox. Signal 2006, 8:2061-2073.
42. Browne S.E, Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
43. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 1999, 9:147-163.
44. Brundin P., Nilsson O.G., Strecker R.E., Lindvall O., Astedt B., Bjorklund A. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp. Brain Res. 1986, 65:235-240.
45. Brustovetsky N., LaFrance R., Purl K., Brustovetsky T., Keene C., Low W., Dubinsky J. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's disease. J. Neurochem. 2005, 93:1361-1370.
46. Bruyn G.W., Bots G.T., Dom R. Current neuropathological status, In Huntington's disease. Advances in Neurology 1979, 23:83-93. Huntington's chorea.
47. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998, 87:49-53.
48. Calabrese V., Guagliano E., Sapienza M., Mancuso C., Butterfield D.A., Stella A.M. Redox regulation of cellular stress response in neurodegenerative disorders. Ital. J. Biochem. 2006, 55:263-282.
49. Cankurtaran E.S., Ozalp E., Soygur H., Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J. Natl. Med. Assoc. 2006, 98:1353-1355.
50. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23:961-969.
51. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R Soc. Lond. B Biol. Sci. 1999, 354:981-989.
52. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci.. 2000, 23:387-392.
53. Chakrabarti S., Bhattacharyya D., Dasgupta D. Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: roles of minor groove width and ligand flexibility. Biopolymers 2000, 56:85-95.
54. Chan T.S., Wilson J.X., O'Brien P.J. Coenzyme Q cytoprotective mechanisms. Methods Enzymol. 2004, 382:89-104.
55. Chang D.T., Rintoul G.L., Pandipati S., Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 2006, 22:388-400.
56. Chaturvedi R.K., Adhihetty P., Shukla S., Hennessy T., Calingasan N., Yang L., Starkov A., Kiaei M., Cannella M., Sassone J., Ciammola A., Squitieri F., Beal M.F. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 2009, 18:3048-3065.
57. Chen H., Chan D.C. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases, Hum. Mol. Genet. 2009, 18:R169-R176.
58. Chen M., Ona V.O., Li M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 797-801.
59. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
60. Chopra V., Fox J., Lieberman G., Dorsey K., Matson W., Waldmeier P., Housman D., Kazantsev A., Young A.B., Hersch S. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. USA 2007, 104:16685-16689.
61. Ciechanover A. The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology 2006, 66:S7-S19.
62. Clifford J.J., Drago J., Natoli A.L. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002, 109:81-88.
63. Coyle J.T., Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263:244-246.
64. Crossman A.R., Mitchell I.J., Sambrook M.A., Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain 1988, 111(Pt 5):1211-1233.
65. Crossman A.R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987, 21:1-40.
66. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
67. Davies S.W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., Bates G.P. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?. Lancet 1998, 351:131-133.
68. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 2002, 22:3473-3483.
69. Deckel A.W., Robinson R.G., Coyle J.T., Sanberg P.R. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. Eur. J. Pharmacol. 1983, 93:287-288.
70. Dedeoglu A, Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 2002, 22:8942-8950.
71. Dedeoglu A., Kubilus J.K., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 2003, 85:1359-1367.
72. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci.. 1990, 13:281-285.
73. DiFiglia M., Sapp E.C.K., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A. Huntington is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
74. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
75. Djousse L., Knowlton B., Hayden M., et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington's disease. Am. J. Med. Genet. A 2003, 119:279-282.
76. Domercq M., Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci. 2004, 25:609-612.
77. Dragunow M., Faull R.L., Lawlor P., Beilharz E.J., Singleton K., Walker E.B., Mee E. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995, 6:1053-1057.
78. Driggers W.J., Holmquist G.P., LeDoux S.P., Wilson G.L. Mapping frequencies of endogenous oxidative damage and the kinetic response to oxidative stress in a region of rat mtDNA. Nucleic Acids Res. 1997, 25:4362-4369.
79. Du Y., Ma Z., Lin S. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2001, 98:14669-14674.
80. Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov. Disord. 2006, 21:530-533.
81. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
82. Dunnett S.B., Rosser A.E. Cell transplantation for Huntington's disease should we continue?. Brain Res. Bull. 2007, 72:132-147.
83. Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., Dufour N., Guillermier M., Brouillet E., Hantraye P., Deglon N., Ferrante R.J., Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 2010, 19:3053-3067.
84. Fan M.M., Fernandes H.B., Zhang L.Y., Hayden M.R., Raymond L.A. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27:3768-3779.
85. Fasano A., Cadeddu F., Guidubaldi A., et al. The long-term effect of tetrabenazine in the management of Huntginton disease. Clin. Neuropharmacol. 2008, 31:313-318.
86. Feigin A., Kieburtz K., Como P., Hickey C., Claude K., Abwender D., Zimmerman C., Steinberg K., Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 1996, 11:321-323.
87. Fernandes H.B., Baimbridge K.G., Church J., Hayden M.R., Raymond L.A. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J. Neurosci. 2007, 27:13614-13623.
88. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230:561-563.
89. Ferrante R.J., Kowall N.W., Richardson E.P., Bird E.D., Martin J.B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 1986, 71:283-288.
90. Ferrante R.J., Beal M.F., Kowall N.W., Richardson E.P., Martin J.B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 1987, 411:162-166.
91. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 1993, 119:46-71.
92. Ferrante R.J., Beal M.F., Kowall N.W. Mechanisms of neuronal degeneration in Huntington's disease. The Basal Ganglia IV: New Ideas and Data on Structure and Function 1994, 149-161. Plenum Press, New York. G. Percheron, J.S. McKenzie, J. Feger (Eds.).
93. Ferrante R.J, Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown R.H., Beal M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 1997, 69:2064-2074.
94. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 2000, 20:4389-4397.
95. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 2002, 22:1592-1599.
96. Ferrante R.J., Kubilus J.K., Lee J., Ryu H., Beesen A., Zucker B., Smith K., Kowall N.W., Ratan R.R., Luthi-Carter R., Hersch S.M. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
97. Ferrante R.J., Ryu H., Kubilus J.K., D'Mello S., Sugars K.L., Lee J., Lu P., Smith K., Browne S., Beal M.F., Kristal B.S., Stavrovskaya I.G., Hewett S., Rubinsztein D.C., Langley B., Ratan R.R. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 2004, 24:10335-10342.
98. Ferrante K.L., Shefner J., Zhang H., Betensky R., O'Brien M., Yu H., Fantasia M., Taft J., Beal M.F., Traynor B., Newhall K., Donofrio P., Caress J., Ashburn C., Freiberg B., O'Neill C., Paladenech C., Walker T., Pestronk A., Abrams B., Florence J., Renna R., Schierbecker J., Malkus B., Cudkowicz M. Tolerance of high-dose (3,000mg/day) coenzyme Q10 in ALS. Neurology 2005, 65:1834-1836.
99. Ferrante, R.J., Kowall, N.W., Hersch, S.M., Brown, R.H., and Beal, M.F. (1996). Immunohistochemical localization of markers of oxidative injury in Huntington's disease., in: 26th Annual Meeting of the Society for Neuroscience, Washington, DC.
100. Fink J.S., Schumacher J.M., Ellias S.L., Palmer E.P., Saint-Hilaire M., Shannon K., Penn R., Starr P., VanHorne C., Kott H.S., Dempsey P.K., Fischman A.J., Raineri R., Manhart C., Dinsmore J., Isacson O. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant. 2000, 9:273-278.
101. Foran, E., Del Signore, S., Markey, A., Matson, S., Smith, K., Cormier, K., Stack, E.C., Hersch, S., Ryu, H., and Ferrante, R.J. (2006). Dose ranging and efficacy study of high-dose creatine in Huntington's disease mouse models, Society for Neuroscience Abstracts.
102. Fox J.H., Connor T., Chopra V., Dorsey K., Kama J.A., Bleckmann D., Betschart C., Hoyer D., Frentzel S., Difiglia M., Paganetti P., Hersch S.M. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Mol. Neurodegener. 2010, 5:26.
103. Friedlander R. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 2003, 348:1365-1375.
104. Froyland L., Madsen L., Vaagenes H. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J. Lipid Res. 1997, 38:1851-1858.
105. Gabrielson K.L., Hogue B.A., Bohr V.A., Cardounel A.J., Nakajima W., Kofler J., Zweier J.L., Rodriguez E.R., Martin L.J., de Souza-Pinto N.C., Bressler J. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am. J. Pathol. 2001, 159:1507-1520.
106. Gardian G., Browne S., Choi D. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 2005, 280:556-563.
107. Gatchel J, Zoghbi H. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 2005, 6:743-755.
108. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
109. Gray M., Shirasaki D., Cepeda C., Andre V., Wilburn B., Lu X., Tao J., Yamazaki I., Li S., Sun Y., Li X., Levine M., Yang X. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
110. Greenberg S.M., Bacskai B.J., Hyman B.T. Alzheimer disease's double-edged vaccine. Nat. Med. 2003, 9:389-390.
111. Group H.S. Tetrabeazine as antichoea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66:366-372.
112. Grunewald T., Beal M.F. Bioenergetics in Huntington's disease. Ann. NY Acad. Sci. 1999, 893:203-213.
113. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997, 79:45-56.
114. Guyot M.C., Palfi S., Stutzmann J.M., Maziere M., Hantraye P., Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 1997, 81:141-149.
115. Hake S.B., Allis C.D. Histone H3 variants and their potential role in indexing mammalian genomes: the " H3 barcode hypothesis" Proc. Natl. Acad. Sci. USA 2006, 103:6428-6435.
116. Han Y, Giroux A., Colucci J., Bayly C.I., McKay D.J., Roy S., Xanthoudakis S., Vaillancourt J., Rasper D.M., Tam J., Tawa P., Nicholson D.W., Zamboni R.J. Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:1173-1180.
117. Hannan A.J. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease. Acta Biochim. Pol. 2004, 51:415-430.
118. Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 1999, 96:8727-8732.
119. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur J. Neurosci. 2001, 14:1492-1504.
120. Hansson O, Castilho R.F., Korhonen L., Lindholm D., Bates G.P., Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J. Neurochem. 2001, 78:694-703.
121. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 2005, 102:5820-5825.
122. Heckmann J.M., Legg P., Sklar D., Fine J., Bryer A., Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004, 63:597-598. author reply 597-598.
123. Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., Nordhoff E., Lurz R., Schugardt N., Rautenberg S., Herhaus C., Barnickel G., Bottcher H., Lehrach H., Wanker E.E. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. USA 2002, 99(Suppl 4):16400-16406.
124. Helder D.I., Kaptein A.A., van Kempen G.M., van Houwelingen J.C., Roos R.A. Impact of Huntington's disease on quality of life. Mov. Disord. 2001, 16:325-330.
125. Heng M., Tallaksen-Greene S., Detloff P.J., Albin R.L. Longitudinal evaulation of the Hdh(CAG) 150 knock-in murine model of Huntington's disease. J. Neurosci. 2007, 27:8989-8998.
126. Hersch S.M., Ferrante R.J. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 2004, 1:298-306.
127. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R.J., Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
128. Hickey M.A, Reynolds G.P., Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 2002, 81:46-59.
129. Hickey M.A., Kosmalska A., Enayati J., Cohen R., Zeitlin S., Levine M.S., Chesselet M.F. Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience 2008, 157:280-295.
130. Hockly E., Cordery P., Woodman B., Mahal A., Van Dellen A., Blakemore C., Lewis C., Hannan A., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
131. Hockly E., Richon V., Woodman B. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100:2041-2046.
132. Hodgson J.G., Smith D.J., McCutcheon K., Koide H.B., Nishiyama K., Dinulos M.B., Stevens M.E., Bissada N., Nasir J., Kanazawa I., Disteche C.M., Rubin E.M., Hayden M.R. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum. Mol. Genet. 1996, 5:1875-1885.
133. Hodgson J., Agopyan N., Gutekunst C.A., Leavitt B.R., Lepiane F., Singaraja R., Smith D., Bissada N., McCutcheon K., Nasir J., Jarnot L., Xi X., Stevens M., Rosemond E., Roder J., Phillips A., Rubin E., Hersch S., Hayden M. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
134. Hoffner G., Kahlem P., Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J. Cell Sci. 2002, 115:941-948.
135. Hogarth P, Lovrecic L., Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov. Disord. 2007, 22:1962-1964.
136. Holmberg C.I., Staniszewski K.E., Mensah K.N., Matouschek A., Morimoto R.I. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J. 2004, 23:4307-4318.
137. Huntington G. On chorea. Med. Surg. Rep. 1872, 317-321.
138. Huntington Study Group A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001, 57:397-404.
139. A futility study of minocycline in Huntington's disease. Mov. Disord. 2010, 25:2219-2224. Huntington Study Group DOMINO Investigators.
140. Minocycline safety and tolerability in Huntington disease. Neurology 2004, 63:547-549. Huntington Study Group.
141. Igarashi S., Koide R., Shimohata T., Yamada M., Hayashi Y., Takano H., Date H., Oyake M., Sato T., Sato A., Egawa S., Ikeuchi T., Tanaka H., Nakano R., Tanaka K., Hozumi I., Inuzuka T., Takahashi H., Tsuji S. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998, 18:111-117.
142. Isacson O., Dunnett S.B., Bjorklund A. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA 1986, 83:2728-2732.
143. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 2000, 23:239-245.
144. Jenkins N.A., Schilling G., Copeland N.G., Becher M.W., Price D.L., Sharp A.H., Jinnah H.A., Ross C.A., Borchelt D.R., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing amutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
145. Jenkins B.G., Klivenyi P., Kustermann E. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74:2108-2119.
146. Jergelsma G. Nue anatomische befunde bei paralysis agitans und bei chronischer progressiver chorea. Neurol. Centralbl. 1908, 27:995-996.
147. Jervis G.A. Huntington's chorea in childhood. Arch. Neurol. 1963, 9:244-257.
148. Kann O., Kovacs R. Mitochondria and neuronal activity. Am. J. Physiol. Cell. Physiol. 2007, 292:C641-C657.
149. Karpuj M.V., Garren H., Slunt H., Price D.L., Gusella J., Becher M.W., Steinman L. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. USA 1999, 96:7388-7393.
150. Karpuj M., Becher M., Springer J. Prolonged survival and decreased abnormal movements in transgenic model of Huntington's disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 2002, 8:143-149.
151. Kieburtz K., McDermott M.P., Voss T.S., Corey-Bloom J., Deuel L.M., Dorsey E.R., Factor S., Geschwind M.D., Hodgeman K., Kayson E., Noonberg S., Pourfar M., Rabinowitz K., Ravina B., Sanchez-Ramos J., Seely L., Walker F., Feigin A. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch. Neurol. 2010, 67:154-160.
152. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
153. Kim J., Amante D.J., Moody J.P., Edgerly C.K., Bordiuk O.L., Smith K., Matson S.A., Matson W.R., Scherzer C.R., Rosas H.D., Hersch S.M., Ferrante R.J. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim. Biophys. Acta 2010, 1802:673-681.
154. Klement I.A., Skinner P.J., Kaytor M.D., Yi H., Hersch S.M., Clark H.B., Zoghbi H.Y., Orr H.T. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998, 95:41-53.
155. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999, 5:347-350.
156. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.E., Beal M.F. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J. Neurochem. 2003, 86:267-272.
157. Knott A.B., Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann. N.Y. Acad. Sci. 2008, 1147:283-292.
158. Kopyov O.V., Jacques S., Lieberman A., Duma C.M., Eagle K.S. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp. Neurol. 1998, 149:97-108.
159. Koroshetz W., Jenkins B., Rosen B., Beal M. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41:160-165.
160. Kremer B., Goldberg P., Andrew S.E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E., et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N. Engl. J. Med. 1994, 330:1401-1406.
161. Kuemmerle S., Gutekunst C.A., Klein A.M., Li X.J., Li S.H., Beal M.F., Hersch S.M., Ferrante R.J. Huntington aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 1999, 46:842-849.
162. Kuhl D., Phelps M., Markham C., Metter E., Riege W., Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 1982, 12:425-434.
163. Laforet G.A., Sapp E., Chase K., McIntyre C., Boyce F.M., Campbell M., Cadigan B.A., Warzecki L., Tagle D.A., Reddy P.H., Cepeda C., Calvert C.R., Jokel E.S., Klapstein G.J., Ariano M.A., Levine M.S., DiFiglia M., Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J. Neurosci. 2001, 21:9112-9123.
164. Landwehrmeyer G, Dubois B., de Yebenes J., Kremer B., Gaus W., Kraus P., Przuntek H., Dib M., Doble A., Fischer W., Ludolph A. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 2007, 62:262-272.
165. Leavitt B.R., Van Raamsdonk J., Shehadeh J., Fernandes H., Murphy Z., Graham R., Wellington C., Raymond L., Hayden M. Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 2006, 96:1121-1129.
166. Lee H.C., Wei Y.H. Mitochondrial role in life and death of the cell. J. Biomed. Sci. 2000, 7:2-15.
167. Lee S.T., Chu K., Park J.E., Kang L., Ko S.Y., Jung K.H., Kim M. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res. 2006, 1118:199-207.
168. Lesort M, Chun W., Johnson G.V., Ferrante R.J. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 1999, 73:2018-2027.
169. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
170. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
171. Lin J., Wu P.H., Tarr P.T., Lindenberg K.S., St-Pierre J., Zhang C.Y., Mootha V.K., Jager S., Vianna C.R., Reznick R.M., Cui L., Manieri M., Donovan M.X., Wu Z., Cooper M.P., Fan M.C., Rohas L.M., Zavacki A.M., Cinti S., Shulman G.I., Lowell B.B., Krainc D., Spiegelman B.M. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004, 119:121-135.
172. Lin J., Yang R., Tarr P.T., Wu P.H., Handschin C., Li S., Yang W., Pei L., Uldry M., Tontonoz P., Newgard C.B., Spiegelman B.M. Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 2005, 120:261-273.
173. Lipton S.A Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004, 1:101-110.
174. Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M., Song J.J., Hammond S.M., Joshua-Tor L., Hannon G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437-1441.
175. Lonergan P.E., Martin D.S., Horrobin D.F., Lynch M.A. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to γ-irradiation. J. Biol. Chem. 2002, 277:20804-20811.
176. Lorand L., Siefring G.E., Lowe-Krentz L. Formation of gamma-glutamyl-epsilon-lysine bridges between membrane proteins by a Ca2+-regulated enzyme in intact erythrocytes. J. Supramol. Struct. 1978, 9:427-440.
177. Lucetti C., Del Dotto P., Gambaccini G., Dell' Agnello G., Bernardini S., Rossi G., Murri L., Bonuccelli U. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003, 60:1995-1997.
178. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J. Neurol. Sci 1991, 18:492-498.
179. Ludolph A.C, Seelig M., Ludolph A. 3-Nitropropionic acid decreases cellular energy levels and causes neuronal degeneration in cortical explants. Neurodegeneration 1992, 1:151-161.
180. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lakshmi Srinidhi C.L., Barnes G., Taylor S.A., James M., Groot N., MacFarlane H., Jenkins B., Anderson M.A., Wexler N.S., Gusella J.F., Bates G.P., Baxendale S., Hummerich H., Kirby S., North M., Youngman S., Mott R., Zehetner G., Sedlacek Z., Poustka A., Frischauf A.-M., Lehrach H., Buckler A.J., Church D., Doucette-Stamm L., O'Donovan M.C., Riba-Ramirez L., Shah M., Stanton V.P., Strobel S.A., Draths K.M., Wales J.L., Dervan P., Housman D.E., Altherr M., Shiang R., Thompson L., Fielder T., Wasmuth J.J., Tagle D., Valdes J., Elmer L., Allard M., Castilla L., Swaroop M., Blanchard K., Collins F.S., Snell R., Holloway T., Gillespie K., Datson N., Shaw D., Harper P.S., Group T.H.s.D.C.R. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
181. Mancuso C., Scapagini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci. 2007, 12:1107-1123.
182. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
183. Mann V.M., Cooper J.M., Javoy-Agid F., Agid Y., Jenner P., Schapira A.H. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990, 336:749.
184. Maragos W.F., Jakel R.J., Pang Z., Geddes W.J. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp. Neurol. 1998, 154:637-644.
185. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 1998, 18:156-163.
186. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA 1998, 95:8892-8897.
187. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 1999, 157:142-149.
188. McBride J.L., Ramaswamy S., Gasmi M., Bartus R.T., Herzog C.D., Brandon E.P., Zhou L., Pitzer M.R., Berry-Kravis E.M., Kordower J.H. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 2006, 103:9345-9350.
189. McBride J.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 2008, 105:5868-5873.
190. McDowell G.A., Town M.M., van't Hoff W., Gahl W.A. Clinical and molecular aspects of nephropathic cystinosis. J. Mol. Med. 1998, 76:295-302.
191. McGeer E.G., McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976, 263:517-519.
192. McGeer E.G., McGeer P.L., Singh K. Kainate-induced degeneration of neostriatal neurons: dependency upon corticostriatal tract. Brain Res. 1978, 139:381-383.
193. McLin J.P., Thompson L.M., Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J. Neurosci. 2006, 24:3134-3140.
194. Meade C.A., Deng Y.P., Fusco F.R., Del Mar N., Hersch S., Goldowitz D., Reiner A. Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol. 2002, 449:241-269.
195. Mecocci P., MacGarvey U., Kaufman A.E., Koontz D., Shoffner J.M., Wallace D.C., Beal M.F. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 1993, 34:609-616.
196. Meldrum A., Dunnett S.B., Everitt B.J. Role of corticostriatal and nigrostriatal inputs in malonate-induced striatal toxicity. Neuroreport 2001, 12:89-93.
197. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 2003, 465:11-26.
198. Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci. Lett. 2001, 310:117-120.
199. Naver B., Stub C., Moller M., Fenger K., Hansen A., Hasholt L., Sorensen S. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
200. Nguyen H.P., Kobbe P., Rahne H., Worpel T., Jager B., Stephan M., Pabst R., Holzmann C., Riess O., Korr H., Kantor O., Petrasch-Parwez E., Wetzel R., Osmand A., von Horsten S. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum. Mol. Genet. 2006, 15:3177-3194.
201. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
202. Novelli A., Reilly J.A., Lysko P.G., Henneberry R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451:205-212.
203. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
204. O'Gorman E., Beutner G., Dolder M., Koretsky A.P., Brdiczka D., Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997, 414:253-257.
205. Olney J.W. Neurotoxicity of excitatory amino acids. Kainic acid as a tool in neurobiology 1978, 95-122. Raven Press, New York. E.G.M. John W. Olney, P.L. McGeer (Eds.).
206. Ondo W.G, Mejia N.I., Hunter C.B. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat. Disord. 2007, 13:453-454.
207. Ordway J.M., Tallaksen-Greene S., Gutekunst C.A., Bernstein E.M., Cearley J.A., Wiener H.W., Dure L.S.t., Lindsey R., Hersch S.M., Jope R.S., Albin R.L., Detloff P.J. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997, 91:753-763.
208. O'Suilleabhain P, Dewey R.B. A randomized trial of amantadine in Huntington disease. Arch. Neurol. 2003, 60:996-998.
209. Palfi S., Riche D., Brouillet E., Guyot M.C., Mary V., Wahl F., Peschanski M., Stutzmann J.M., Hantraye P. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp. Neurol. 1997, 146:135-141.
210. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
211. Parker W.D., Boyson S.J., Luder A.S., Parks J.K. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990, 40:1231-1234.
212. Perez-Severiano F., Rios C., Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 2000, 862:234-237.
213. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979, 204:643-647.
214. Petersen A., Chase K., Puschban Z., DiFiglia M., Brundin P., Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 2002, 175:297-300.
215. Petersen A., Puschban Z., Lotharius J., NicNiocalli B., Wiekop P., O'Connor W., Brundin P. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic model Huntington's disease transgenic mice. Neurobiol. Dis. 2002, 11:134-146.
216. Pickart C.M., VanDemark A.P. Opening doors into the proteasome. Nat. Struct. Biol. 2000, 7:999-1001.
217. Polidori M.C., Mecocci P., Browne S.E., Senin U., Beal M.F. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 1999, 272:53-56.
218. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 1995, 15:3775-3787.
219. Puri B.K., Bydder G.M., Counsell S.J. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002, 13:123-126.
220. Puri B.K., Leavitt B.R., Hayden M.R., Ross C.A., Rosenblatt A., Greenamyre J.T., Hersch S., Vaddadi K.S., Sword A., Horrobin D.F., Manku M., Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286-292.
221. Quinn N., Brown R., Craufurd D., Goldman S., Hodges J., Kieburtz K., Lindvall O., MacMillan J., Roos R. Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT-HD). Mov. Disord. 1996, 11:143-150.
222. Rabbani A, Finn R.M., Thambirajah A.A., Ausio J. Binding of antitumor antibiotic daunomycin to histones in chromatin and in solution. Biochemistry 2004, 43:16497-16504.
223. Ramaswamy S., Shannon K., Kordower J. Huntington's disease: pathological mechanisms and therpeutic strategies. Cell Transplant. 2007, 16:301-312.
224. Ramaswamy, S., McBride, J.L., Zhou, L., Han, I., Berry-Kravis, E.M., Herzog, C.D., Gasmi, M., Partus, R.T., and Kordower, J.H. Cognitive deficits in the N171-82Q transgenic mouse model of Huntington's disease, Cell Transplant, Special issue for the American Society for Neural Therapy and Repair.
225. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11:1107-1117.
226. Ravikumar B., Stewart A., Kita H., Kato K., Duden R., Rubinsztein D.C. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum. Mol. Genet. 2003, 12:985-994.
227. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004, 36:585-595.
228. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O., Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998, 20:198-202.
229. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. USA 1988, 85:5733-5737.
230. Revesz I., Modig H. Cysteamine-induced increase of cellular glutathione-level: a new hypothesis of the radioprotective mechanism. Nature 1965, 207:430-431.
231. Reynolds D.S., Carter R.J., Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 1998, 18:10116-10127.
232. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 2001, 276:14545-14548.
233. Rigamonti D., Bauwe J., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., Cattaneo E. Wild-type Huntington's disease in peripheral blood. Proc. Natl. Acad. Sci. USA 2007, 104.
234. Rigamonti D., Bauer J., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M., Li Y., Cooper J.K., Ross C., Govoni S., Vincenz C., Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2007, 20:3705-3713.
235. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
236. Rohas L.M., St-Pierre J., Uldry M., Jager S., Handschin C., Spiegelman B.M. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7933-7938.
237. Rosas H.D., Koroshetz W.J., Jenkins B.G., Chen Y.I., Hayden D.L., Beal M.F., Cudkowicz M.E. Riluzole therapy in Huntington's disease (HD). Mov. Disord. 1999, 14:326-330.
238. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58.
239. Rosas H.D., Tuch D.S., Hevelone N.D., Zaleta A.K., Vangel M., Hersch S.M., Salat D.H. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov. Disord. 2006, 21:1317-1325.
240. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008, 131:1057-1068.
241. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl):S10-S17.
242. Rubinsztein D.C. How does the Huntington's disease mutation damage cells?. Sci. Aging Knowledge Environ. 2003, 2003:PE26.
243. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
244. Ryu H., Rosas H.D., Hersch S.M., Ferrante R.J. The therapeutic role of creatine in Huntington's disease. Pharmacol. Ther. 2005, 108:193-207.
245. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. USA 2006, 103:19176-19181.
246. Sah D.W. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006, 79:1773-1780.
247. Sanchez I., Mahike C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine in neurodegenerative disorders. Nature 2003, 421:373-379.
248. Sarkar S., Rubinsztein D.C. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J 2008, 275:4263-4270.
249. Sarkar S., Floto R.A., Berger Z., Imarisio S., Cordenier A., Pasco M., Cook L.J., Rubinsztein D.C. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell. Biol. 2005, 170:1101-1111.
250. Sarkar S., Perlstein E.O., Imarisio S., Pineau S., Cordenier A., Maglathlin R.L., Webster J.A., Lewis T.A., O'Kane C.J., Schreiber S.L., Rubinsztein D.C. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 2007, 3:331-338.
251. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
252. Sawa A., Nagata E., Sutcliffe S., Dulloor P., Cascio M.B., Ozeki Y., Roy S., Ross C.A., Snyder S.H. Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts. Neurobiol. Dis. 2005, 20:267-274.
253. Schiefer J., Landwehrmeyer G.B., Luesse H.G., Sprunken A., Puls C., Milkereit A., Milkereit E., Kosinski C.M. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov. Disord. 2002, 17:748-757.
254. Schilling G., Coonfield M.I., Ross C.A., Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 2001, 215:149-153.
255. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
256. Schmidt R.H., Bjorklund A., Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 1981, 218:347-356.
257. Schulz J.B., Henshaw D.R., Siwek D., Jenkins B.G., Ferrante R.J., Cipolloni P.B., Kowall N.W., Rosen B.R., Beal M.F. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 1995, 64:2239-2247.
258. Schulz J.B., Matthews R.T., Jenkins B.G., Ferrante R.J., Siwek D., Henshaw D.R., Cipolloni P.B., Mecocci P., Kowall N.W., Rosen B.R., et al. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci. 1995, 15:8419-8429.
259. Schumacher J.M., Hantraye P., Brownell A.L., Riche D., Madras B.K., Davenport P.D., Maziere M., Elmaleh D.R., Brownell G.L., Isacson O. A primate model of Huntington's disease: functional neural transplantation and CT-guided stereotactic procedures. Cell Transplant. 1992, 1:313-322.
260. Seppi K., Mueller J., Bodner T., Brandauer E., Benke T., Weirich-Schwaiger H., Poewe W., Wenning G. Riluzole in Huntington's disease (HD): an open label study with one year follow up. J. Neurol. 2001, 248:866-869.
261. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 1999, 8:763-774.
262. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 2002, 59:1541-1550.
263. Shults C.W., Flint Beal M., Song D., Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 2004, 188:491-494.
264. Sisodia S.S. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?. Cell 1998, 95:1-4.
265. Slow E, van Raamsdonk J., Rogers D., Coleman S., Graham R., Deng Y., Oh R., Bissada N., Hossain S., Yang Y., Li X., Simpson E., Gutekunst C.A., Leavitt B.R., Hayden M. Selective striatal neuron loss in a YAC128 mouse model of Huntington's disease. Hum. Mol. Genet. 2003, 12:1555-1567.
266. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., Leavitt B.R., Hayden M.R. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 2005, 102:11402-11407.
267. Smith K.M., Matson S., Matson W.R., Cormier K., Del Signore S.J., Hagerty S.W., Stack E.C., Ryu H., Ferrante R.J. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:616-626.
268. Sohal R.S., Brunk U.T. Lipofuscin as an indicator of oxidative stress and aging. Adv. Exp. Med. Biol. 1989, 266:17-26.
269. Somwar R, Sumitani S., Taha C., Sweeney G., Klip A. Temporal activation of p70 S6 kinase and Akt1 by insulin: PI 3-kinase-dependent and -independent mechanisms. Am. J. Physiol. 1998, 275:E618-E625.
270. Squitieri F., Orobello S., Cannella M., Martino T., Romanelli P., Giovacchini G., Frati L., Mansi L., Ciarmiello A. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:1113-1120.
271. Stack E.C., Ferrante R.J. Huntington's disease: progress and potential in the field. Expert Opin. Investig. Drugs 2007, 16:1933-1953.
272. Stack E.C, Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., Ryu H., Hersch S.M., Ferrante R.J. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol. 2005, 490:354-370.
273. Stack E.C., Smith K.M., Ryu H., Cormier K., Chen M., Hagerty S.W., Del Signore S.J., Cudkowicz M.E., Friedlander R.M., Ferrante R.J. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 2006, 1762:373-380.
274. Stack E.C., Dedeoglu A., Smith K.M., Cormier K., Kubilus J.K., Bogdanov M., Matson W.R., Yang L., Jenkins B.G., Luthi-Carter R., Kowall N.W., Hersch S.M., Beal M.F., Ferrante R.J. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 2007, 27:12908-12915.
275. Stack E.C., Del Signore S.J., Luthi-Carter R., Soh B.Y., Goldstein D.R., Matson S., Goodrich S., Markey A.L., Cormier K., Hagerty S.W., Smith K., Ryu H., Ferrante R.J. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 2007, 16:1164-1175.
276. Steffan J., Bodai L., Pallos J. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
277. Storey E., Hyman B.T., Jenkins B., Brouillet E., Miller J.M., Rosen B.R., Beal M.F. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 1992, 58:1975-1978.
278. Storey E., Cipolloni P.B., Ferrante R.J., Kowall N.W., Beal M.F. Movement disorder following excitotoxin lesions in primates. Neuroreport 1994, 5:1259-1261.
279. Stoy N., Mackay G.M., Forrest C.M., Christofides J., Egerton M., Stone T.W., Darlington L.G. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 2005, 93:611-623.
280. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
281. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19:233-238.
282. Sun Z., Xie J., Reiner A. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp. Neurol. 2002, 176:55-65.
283. Sun Z., Chen Q., Reiner A. Enkephalinergic striatal projection neurons become less affected by quinolinic acid than substance P-containing striatal projection neurons as rats age. Exp. Neurol. 2003, 184:1034-1042.
284. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., Cooper J.M., Schapira A.H. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 2000, 47:80-86.
285. Tabrizi S.J., Blamire A.M., Manners D.N. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003, 61:141-142.
286. Tabrizi S.J., Blamire A.M., Manners D.N., Rajagopalan B., Styles P., Schapira A.H., Warner T.T. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005, 64:1655-1656.
287. Tabrizi, S., Durr, A., Roos, R., Leavitt, B.R., Jones, R., Landwehrmeyer, B., Johnson, H., Hicks, S., Kennard, C., Reilmann, R., Crauford, D., Rosas, H.D., Frost, C., Langbehn, D., Scahill, R., and Stout, J. (2010). Significant biological and clinical change detected over one year in premanifest and early stage Huntington's disease in the TRACK-HD study, in: The Milton Wexler Celebration of Life, Cambridge, MA.
288. Tallaksen-Greene S.J., Crouse A.B., Hunter J.M., Detloff P.J., Albin R.L. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience 2005, 131:843-852.
289. Taylor J.P., Tanaka F., Robitschek J., Sandoval C.M., Taye A., Markovic-Plese S., Fischbeck K.H. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 2003, 12:749-757.
290. Taylor-Robinson S.D., Weeks R.A., Bryant D.J., Sargentoni J., Marcus C.D., Harding A.E., Brooks D.J. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord 1996, 11:167-173.
291. Tellez-Nagel I., Johnson A.B., Terry R.D. Studies on brain biopsies of patients with Huntington's chorea. J Neuropathol Exp. Neurol. 1974, 33:308-332.
292. Teng Y.D., Choi H., Onario R.C., Zhu S., Desilets F.C., Lan S., Woodard E.J., Snyder E.Y., Eichler M.E., Friedlander R.M. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA 2004, 101:3071-3076.
293. Terman A., Brunk U.T. Lipofuscin: mechanisms of formation and increase with age. Apmis 1998, 106:265-276.
294. Thomas M., Ashizawa T., Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov. Disord. 2004, 19:692-695.
295. Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., Koistinaho J. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 2001, 21:2580-2588.
296. Toulmond S., Tang K., Bureau Y., Ashdown H., Degen S., O'Donnell R., Tam J., Han Y., Colucci J., Giroux A., Zhu Y., Boucher M., Pikounis B., Xanthoudakis S., Roy S., Rigby M., Zamboni R., Robertson G.S., Ng G.Y., Nicholson D.W., Fluckiger J.P. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br. J. Pharmacol. 2004, 141:689-697.
297. Traynor B.J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S.C., Cudkowicz M.E. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006, 67:20-27.
298. Urbani A., Belluzzi O. Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur. J. Neurosci. 2000, 12:3567-3574.
299. Van Raamsdonk J., Warby S., Hayden M. Selective degeneration in YAC mouse models of Huntington's disease. Brain Res. Bull. 2007, 72:124-131.
300. Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van Leemputte M., Hespel P., Dom R. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003, 61:925-930.
301. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., Chase T.N. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002, 59:694-699.
302. von Horsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
303. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. , Neuropathological classification of Huntington's disease. J Neuropathol Exp. Neurol. 1985, 44:559-577.
304. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., Ferrante R.J., Kristal B.S., Friedlander R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2003, 100:10483-10487.
305. Wang H., Lim P.J., Karbowski M., Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 2009, 18:737-752.
306. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
307. Wheeler V., Auerbach W., White J., Srinidhi J., Auerbach A., Ryan A., Duyao M., Vrbanac V., Weaver M., Gusella J., Joyner A., MacDonald M. Length dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 1999, 8:115-122.
308. Wheeler V., White J., Gutekunst C., Vrbanac V., Weaver M., Li X., Li S., Vonsattel Y.H.J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in Hdh92Q and HdhQ111 knock-in mice. Hum. Mol. Genet. 2000, 9:503-513.
309. Wheeler V.C., Gutekunst C.A., Vrbanac V., Lebel L.A., Schilling G., Hersch S., Friedlander R.M., Gusella J.F., Vonsattel J.P., Borchelt D.R., MacDonald M.E. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 2002, 11:633-640.
310. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 1997, 17:404-410.
311. Wu D.C, Jackson-Lewis V., Vila M. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 2002, 22:1763-1771.
312. Wu J., Tang T., Bezprozvanny I. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci. Lett. 2006, 407:219-223.
313. Yamamoto A., Cremona M.L., Rothman J.E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell. Biol. 2006, 172:719-731.
314. Yang S.H, Cheng P.H., Banta H., Piotrowska-Nitsche K., Yang J.J., Cheng E.C., Snyder B., Larkin K., Liu J., Orkin J., Fang Z.H., Smith Y., Bachevalier J., Zola S.M., Li S.H., Li X.J., Chan A.W. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 2008, 453:921-924.
315. Yrjanheikki K., Keinanen R., Pellikka M., Hokfelt T., Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. USA 1998, 95:15769-15774.
316. Yu Z., Li S., Evans J., Pillarisetti A., Li H., Li X. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 2003, 15:2193-2202.
317. Zainelli G.M., Dudek N.L., Ross C.A., Kim S.Y., Muma N.A. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J. Neuropathol Exp. Neurol. 2005, 64:58-65.
318. Zeevalk G.D., Nicklas W.J. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition. J. Pharmacol. Exp. Ther. 1991, 257:870-878.
319. Zeng Y., Yi R., Cullen B.R. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA 2003, 100:9779-9784.
320. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 2002, 33:849-860.
321. Zhang X., Smith D.L., Meriin A.B., Engemann S., Russel D.E., Roark M., Washington S.L., Maxwell M.M., Marsh J.L., Thompson L.M., Wanker E.E., Young A.B., Housman D.E., Bates G.P., Sherman M.Y., Kazantsev A.G. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:892-897.
322. Zhang Y., Leavitt B.R., Van Raamsdonk J., Dragatsis I., Goldowitz D., MacDonald M.E., Hayden M., Friedlander R. Huntingtin inhibits caspase-3 activation. EMBO J. 2006, 25:5896-5906.
323. Zhang H., Li Q., Graham R.K., Slow E., Hayden M.R., Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol. Dis. 2008, 31:80-88.
324. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002, 417:74-78.
325. Zhu S., Li M., Figueroa B.E., Liu A., Stavrovskaya I.G., Pasinelli P., Beal M.F., Brown R.H., Kristal B.S., Ferrante R.J., Friedlander R.M. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 2004, 24:5909-5912.